📊 CLPT Key Takeaways
Investment Thesis
ClearPoint Neuro is a pre-revenue profitability company with severe operational challenges despite solid gross margins of 61.4%. The company is burning significant cash with negative operating cash flow of -$23.9M and free cash flow of -$24.4M, while flat revenue growth and deteriorating net income (-35% YoY) indicate deteriorating fundamentals. With only 45.9M in cash against 49.1M in long-term debt and persistent operating losses of -$24.2M, the company faces severe liquidity stress if losses continue at current rates.
CLPT Strengths
- Strong gross margin of 61.4% indicates efficient production and pricing power
- Solid cash position of $45.9M provides near-term runway
- Excellent liquidity ratios (current ratio 5.91x, quick ratio 5.13x) for short-term obligations
CLPT Risks
- Negative operating income of -$24.2M with no clear path to profitability despite adequate gross margins
- Severe cash burn with negative operating cash flow of -$23.9M and free cash flow of -$24.4M
- Stagnant revenue growth (0% YoY) combined with expanding net losses (-35% YoY) indicates operational deterioration
- High leverage with debt-to-equity of 1.75x and long-term debt of $49.1M against stockholders equity of only $28.0M
- Negative interest coverage of -298.3x indicates inability to service debt from operations
- High insider Form 4 activity (29 filings in 90 days) may indicate uncertainty or distress
Key Metrics to Watch
- Quarterly revenue growth and customer acquisition trends
- Operating cash flow and path to cash flow breakeven
- Operating margin improvement and SG&A cost reduction progress
- Cash runway given current burn rate and debt maturity schedule
- Gross margin sustainability under competitive pressure
CLPT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.91x current ratio provides a solid financial cushion.
CLPT Profitability Ratios
CLPT vs Healthcare Sector
How ClearPoint Neuro, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLPT Balance Sheet & Liquidity
CLPT 5-Year Financial Trend
5-Year Trend Summary: ClearPoint Neuro, Inc.'s revenue has grown significantly by 54% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.70 indicates the company is currently unprofitable.
CLPT Growth Metrics (YoY)
CLPT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.1M | -$4.1M | $-0.18 |
| Q2 2025 | $7.9M | -$4.1M | $-0.16 |
| Q1 2025 | $7.6M | -$4.1M | $-0.16 |
| Q3 2024 | $5.8M | -$4.1M | $-0.18 |
| Q2 2024 | $6.0M | -$4.1M | $-0.16 |
| Q1 2024 | $5.4M | -$4.1M | $-0.16 |
| Q3 2023 | $5.1M | -$3.8M | $-0.15 |
| Q2 2023 | $5.2M | -$4.0M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CLPT Capital Allocation
CLPT SEC Filings
Access official SEC EDGAR filings for ClearPoint Neuro, Inc. (CIK: 0001285550)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLPT
What is the AI rating for CLPT?
ClearPoint Neuro, Inc. (CLPT) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLPT's key strengths?
Strong gross margin of 61.4% indicates efficient production and pricing power. Solid cash position of $45.9M provides near-term runway.
What are the risks of investing in CLPT?
Negative operating income of -$24.2M with no clear path to profitability despite adequate gross margins. Severe cash burn with negative operating cash flow of -$23.9M and free cash flow of -$24.4M.
What is CLPT's revenue and growth?
ClearPoint Neuro, Inc. reported revenue of $37.0M.
Does CLPT pay dividends?
ClearPoint Neuro, Inc. does not currently pay dividends.
Where can I find CLPT SEC filings?
Official SEC filings for ClearPoint Neuro, Inc. (CIK: 0001285550) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLPT's EPS?
ClearPoint Neuro, Inc. has a diluted EPS of $-0.90.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.